Suppr超能文献

肿瘤类器官,一种研究肺部定植和预测治疗反应的新型多细胞类器官。

Metastatic Tumor-in-a-Dish, a Novel Multicellular Organoid to Study Lung Colonization and Predict Therapeutic Response.

机构信息

Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas.

Department of General Surgery, University of Kansas Medical Center, Kansas City, Kansas.

出版信息

Cancer Res. 2019 Apr 1;79(7):1681-1695. doi: 10.1158/0008-5472.CAN-18-2602. Epub 2019 Jan 23.

Abstract

Metastasis is a major cause of cancer-related deaths. A dearth of preclinical models that recapitulate the metastatic microenvironment has impeded the development of therapeutic agents that are effective against metastatic disease. Because the majority of solid tumors metastasize to the lung, we developed a multicellular lung organoid that mimics the lung microenvironment with air sac-like structures and production of lung surfactant protein. We used these cultures, called primitive lung-in-a-dish (PLiD), to recreate metastatic disease using primary and established cancer cells. The metastatic tumor-in-a-dish (mTiD) cultures resemble the architecture of metastatic tumors in the lung, including angiogenesis. Pretreating PLiD with tumor exosomes enhanced cancer cell colonization. We next tested the response of primary and established cancer cells to current chemotherapeutic agents and an anti-VEGF antibody in mTiD against cancer cells in two-dimensional (2D) or 3D cultures. The response of primary patient-derived colon and ovarian tumor cells to therapy in mTiD cultures matched the response of the patient in the clinic, but not in 2D or single-cell-type 3D cultures. The sensitive mTiD cultures also produced significantly lower circulating markers for cancer similar to that seen in patients who responded to therapy. Thus, we have developed a novel method for lung colonization , a final stage in tumor metastasis. Moreover, the technique has significant utility in precision/personalized medicine, wherein this phenotypic screen can be coupled with current DNA pharmacogenetics to identify the ideal therapeutic agent, thereby increasing the probability of response to treatment while reducing unnecessary side effects. SIGNIFICANCE: A lung organoid that exhibits characteristics of a normal human lung is developed to study the biology of metastatic disease and therapeutic intervention.

摘要

转移是癌症相关死亡的主要原因。缺乏能够重现转移性微环境的临床前模型,阻碍了针对转移性疾病的治疗药物的发展。由于大多数实体瘤转移到肺部,我们开发了一种多细胞肺类器官,它具有气囊样结构和肺表面活性蛋白的产生,模拟了肺部微环境。我们使用这些培养物,称为原始肺类器官(PLiD),使用原代和已建立的癌细胞重现转移性疾病。转移性肿瘤类器官(mTiD)培养物类似于肺部转移性肿瘤的结构,包括血管生成。用肿瘤外泌体预处理 PLiD 可增强癌细胞定植。接下来,我们在 mTiD 中测试了原代和已建立的癌细胞对当前化疗药物和抗 VEGF 抗体的反应,以及在二维(2D)或 3D 培养物中对癌细胞的反应。原发性患者来源的结肠和卵巢肿瘤细胞在 mTiD 培养物中的治疗反应与患者在临床中的反应相匹配,但与 2D 或单细胞类型 3D 培养物中的反应不匹配。敏感的 mTiD 培养物也产生了与对治疗有反应的患者相似的明显较低的循环癌症标志物。因此,我们开发了一种新的方法用于肺部定植,这是肿瘤转移的最后阶段。此外,该技术在精准/个性化医学中具有重要的应用价值,其中这种表型筛选可以与当前的 DNA 药物遗传学相结合,以确定理想的治疗药物,从而增加对治疗的反应概率,同时减少不必要的副作用。意义:开发了一种具有正常人类肺特征的肺类器官,用于研究转移性疾病和治疗干预的生物学。

相似文献

引用本文的文献

1
Dissecting endothelial cell heterogeneity with new tools.用新工具剖析内皮细胞异质性。
Cell Regen. 2025 Mar 23;14(1):10. doi: 10.1186/s13619-025-00223-3.
5
Organoids derived from metastatic cancers: Present and future.源自转移性癌症的类器官:现状与未来。
Heliyon. 2024 Apr 27;10(9):e30457. doi: 10.1016/j.heliyon.2024.e30457. eCollection 2024 May 15.
6
Advanced lung organoids for respiratory system and pulmonary disease modeling.用于呼吸系统和肺部疾病建模的高级肺类器官
J Tissue Eng. 2024 Feb 22;15:20417314241232502. doi: 10.1177/20417314241232502. eCollection 2024 Jan-Dec.
10
Engineering prostate cancer in vitro: what does it take?体外构建前列腺癌模型:需要做些什么?
Oncogene. 2023 Aug;42(32):2417-2427. doi: 10.1038/s41388-023-02776-6. Epub 2023 Jul 12.

本文引用的文献

2
Overview on Anticancer Drug Design and Development.抗癌药物设计与开发概述。
Curr Med Chem. 2018;25(15):1704-1719. doi: 10.2174/0929867325666171129215610.
8
Surgical treatment of pulmonary metastases in pediatric solid tumors.小儿实体瘤肺转移的外科治疗
Semin Pediatr Surg. 2016 Oct;25(5):311-317. doi: 10.1053/j.sempedsurg.2016.09.001. Epub 2016 Sep 3.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验